Tocilizumab for cerebral amyloid angiopathy-related inflammation with elevated IL-6 levels: A case report
Therapeutic Advances in Neurological Disorders · 2026-11 · 19
DOI: 10.1177/17562864261507601 ↗Kurz gefasst
Fallbericht in der Zeitschrift Therapeutic Advances in Neurological Disorders, online erschienen am 10.11.2026. Verfasst von Jing-Ying Huang und 6 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cerebral amyloid angiopathy-related inflammation (CAA-RI) is a rare neurological disorder that may present with headache, seizures, and focal neurological deficits. Brain magnetic resonance imaging (MRI) typically demonstrates T2-FLAIR white matter hyperintensities, often accompanied by cerebral microbleeds. Although corticosteroids are considered effective for CAA-RI, the role of targeted immunotherapy remains unclear. We report a 66-year-old man who developed progressive visual impairment following an episode of headache and fever. Brain MRI demonstrated extensive bilateral parieto-occipital T2-FLAIR white matter hyperintensities accompanied by multiple cerebral microbleeds, with additional periventricular white matter abnormalities. Interleukin-6 (IL-6) levels were elevated in both serum and cerebrospinal fluid (CSF), whereas autoimmune encephalitis antibody panels were negative in both serum and CSF. Genetic testing revealed an apolipoprotein E (APOE) ε3/ε4 genotype. Based on the clinical presentation, neuroimaging findings, and laboratory results, a diagnosis of probable CAA-RI was made. The patient was treated with corticosteroids and tocilizumab, an IL-6 receptor inhibitor. At the 2-month follow-up, his visual field impairment had improved, serum IL-6 levels had decreased, and follow-up brain MRI demonstrated a marked reduction in the extent of the T2-FLAIR white matter hyperintensities. This case describes markedly elevated CSF IL-6 levels in a patient with CAA-RI. Clinical and radiological improvement was observed over the course of treatment, which included corticosteroids and tocilizumab. Elevated IL-6 may reflect active neuroinflammation. However, its causal role in CAA-RI remains uncertain. Further studies are needed to clarify the role of IL-6 signaling in CAA-RI and to evaluate the efficacy and safety of IL-6-targeted therapy.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, J., Fu, J., Li, Y., Guo, R., Sun, Y., Jia, Z., & Li, B. (2026). Tocilizumab for cerebral amyloid angiopathy-related inflammation with elevated IL-6 levels: A case report. Therapeutic Advances in Neurological Disorders, 19. https://doi.org/10.1177/17562864261507601
Vancouver
Huang J, Fu J, Li Y, Guo R, Sun Y, Jia Z, et al. Tocilizumab for cerebral amyloid angiopathy-related inflammation with elevated IL-6 levels: A case report. Therapeutic Advances in Neurological Disorders. 2026;19. doi:10.1177/17562864261507601
BibTeX
@article{Huang2026,
author = {Huang, Jing-Ying and Fu, Jia and Li, Yin-Shuang and Guo, Ruo-Yi and Sun, Ya-Fei and Jia, Zhen and Li, Bin},
title = {Tocilizumab for cerebral amyloid angiopathy-related inflammation with elevated IL-6 levels: A case report},
journal = {Therapeutic Advances in Neurological Disorders},
year = {2026},
volume = {19},
doi = {10.1177/17562864261507601}
}
EUVIMED